Cardiorenal type 1 syndrome (CRS1) occurs in almost one-fifth of the patients with cardiac disorders, especially in acute decompensated heart failure (ADHF) patients , increasing their mortality by five times. CRS1 presents with a rapidly worsening cardiac function, leading to acute kidney injury (AKI ). Also, venous congestion plays a key role in the pathophysiology of CRS1, thus, making decongestion the primary therapeutic goal.
Intravenous (IV) loop diuretics , mainly furosemide, constitute the standard pharmacotherapy for ADHF; however, many patients develop resistance. Therefore, synergizing the diuretic effect of furosemide with thiazides or spironolactone has been explored — the rationale being that sequential blocking of the renal tubule would enhance the effect of furosemide. Here's a Journal Watch that discusses the study “ The Effect in Renal Function and Vascular…
